Atrial fibrillation (Afib) disorder, is characterised by increased or irregular heart rhythm that increases the risk of stroke, heart failure and other cardiovascular diseases.
The US Food and Drug Administration (FDA) approved wearable patch acts like a sensor and performs active electrocardiography (ECG) screening to detect irregular heart rhythm condition as well as recent heart attacks.
The device resulted in more people receiving critical preventive therapies, which might have gone undiagnosed, said the researchers while emphasising the use of digital medicine technologies to identify undiagnosed Afib disorder in at-risk populations.
"Our study shows an almost threefold improvement in the rate of diagnosis of AFib in the those actively monitored compared to usual care," said Steven Steinhubl, Director of digital medicine at Scripps Translational Science Institute (STSI) in California, US.
"Timely diagnosis of AFib more effectively can enable the initiation of effective therapies and help reduce strokes and death," added Steinhubl, who is also a professor at Scripps Research Institute in the US.
The study, published in the journal JAMA, included data from 5,214 individuals for one year, with one third of the group being assigned to the monitored cohort and the rest being observational controls.
The participants self-applied the wearable sensor patch for two weeks and returned it for analysis.
The team found that six per cent of the group developed Afib and nearly three per cent among the controls developed the disease.
"This study demonstrates the utility of a digital approach not only to diagnosing asymptomatic AFib, but to the clinical research field as a whole," Steinhubl explained.
(This story has not been edited by Social News XYZ staff and is auto-generated from a syndicated feed.)
